

Abstract book  
Poster Pitches  
EAONO  
4-7 September, 2024  
De Vereeniging, Nijmegen, The Netherlands



## Inhoud

PP1.01 Clinical Cost Analysis between Transcutaneous and Percutaneous Bone Conduction Devices .	5
Drs Tjerk Aukema <sup>1</sup> , Drs Emma Teunissen <sup>2</sup> , ir. dr. Arno Janssen <sup>2</sup> , prof. dr. Myrthe Hol <sup>1</sup> , prof. dr. Emmanuel Mylanus <sup>2</sup> .....	5
PP1.02 Intra- and post-operative experiences from 51 surgeries of a new active transcutaneous bone-anchored implant system.....	6
Professor Dr. Myrthe K.S Hol <sup>1</sup> , Professor Emmanuel A.M. Mylanus <sup>2</sup> , Dr. Peter Monksfield <sup>3</sup> , Dr. Rupan Banga <sup>3</sup> , Dr James Tysome <sup>4</sup> , Professor Dr. Manohar Bance <sup>4</sup> , Professor Dr. Susan Arndt <sup>5</sup> , Professor Dr. Thomas Lenarz <sup>6</sup> , Dr. Rolf Salcher <sup>6</sup> , Dr. Kerstin Willenborg <sup>6</sup> , Dr. Nils Prenzler <sup>6</sup> .....	6
PP1.03 Important factors for the outcomes of cochlear implantation in children.....	7
Prof Sanja Spiric <sup>1</sup> .....	7
PP1.04 AC102 – Phase I Results and Phase II Initiation for a New Drug Candidate for the Treatment of Sudden Sensorineural Hearing Loss .....	8
Froukje Cals <sup>1</sup> , Sybren Robijn <sup>1</sup> , Reimar Schlingensliepen <sup>2</sup> , Christin Galetzka <sup>2</sup> , Cris Lanting <sup>1</sup> , Ronald Pennings <sup>1</sup> .....	8
PP1.05 Long-term hearing results for otosclerosis patients receiving cochlear implants - Impact of facial nerve stimulation .....	9
Md, Phd Åsa Bonnard <sup>1,2</sup> , Med Stud Oskar Lindenfors <sup>2</sup> , Martin Eklöf <sup>1,2</sup> .....	9
PP1.06 Advancing Surgical Education and Skill Aquisition with the Exoscope for Cochlear Implantation in a Tertiary Hospital .....	10
Jona Minette Ligon <sup>1</sup> .....	10
PP1.07 Long-term Results of Reverse Fixation Clip Technique on Electrode Migration Rates in a Large Cochlear Implant Cohort.....	11
Georg Schweizer <sup>1</sup> , Lina Maria Serna-Higuita <sup>2</sup> , Agnes Mühle <sup>1</sup> , Dr. med. Philipp Gamerdinger <sup>1</sup> , Dr. med. Thore Schade-Mann <sup>1</sup> , Prof. Dr. med. Dr. oec. Martin Holderried <sup>3</sup> , Dr. med. Steffen Paasch <sup>1</sup> , Prof. Dr. med. Hubert Löwenheim <sup>1</sup> , Dr. med. Anke Tropitzsch <sup>1,4,5</sup> .....	11
PP1.08 Audiological performance of the hearing contact lens Vibrosonic® alpha.....	12
Dr. Fritz Schneider <sup>1</sup> , Dr.-ing. Ernst Dalhoff <sup>1</sup> , Prof. Dr. Hubert Löwenheim <sup>1</sup> .....	12
PP1.09 A prospective multicentre European study investigating a one-step drill system (MONO) for bone anchored hearing procedures – Experience and outcomes at 1 year.....	13
Mr Harry Powell <sup>1</sup> , Dr Tjerk Aukema, Miss Rupan Banga, Prof. dr. Myrthe Hol, Dr Dan Dupont Hougaard, Prof. dr. Emmanuel Mylanus, Dr Måns Eeg Olofsson, Dr Emma Teunissen, Mr James Tysome, Dr Sara Svensson.....	13
PP1.10 ATOH-1 Gene Therapy for Regenerating Hair Cells and Restoring Auditory Function in Mice with Acquired Sensorineural Hearing Loss: A Meta Analysis and Bioinformatic Analysis of Preclinical Studies.....	14
Ahmad Saeed.....	14
PP2.01 Comparison of endoscopic cartilage myringoplasty with and without trimming perforation margins and epithelium of malleus handle for repairing subtotal perforation .....	15
zhengcai Lou <sup>1</sup> .....	15
PP2.02 Comparison of long-term outcome of two endoscopic transtympanic myringoplasty for repairing large chronic perforations .....	16

zhengcai Lou <sup>1</sup> .....	16
PP2.03 Exome variant prioritization in a large cohort of hearing-impaired individuals indicates IKZF2 to be associated with hearing loss and guides future research for unsolved cases .....	17
Hedwig M Velde <sup>1,2</sup> , dr. Jeroen Smits <sup>3</sup> , Jaap Oostrik <sup>1</sup> , dr. Helger Yntema <sup>4</sup> , dr. Lonneke Haer-Wigman <sup>4</sup> , Prof. dr. Martijn Huynen <sup>5</sup> , Prof. dr. Ronald Pennings <sup>1</sup> , Prof. dr. Hannie Kremer <sup>1,4</sup> .....	17
PP2.04 Progressive loss of sensitivity to electrical stimulation after cochlear implantation in X-linked POU3F4 incomplete partition 3 inner ear malformation deafness.....	18
Dr Martin Eklöf <sup>1,2</sup> , Dr Henrik Smeds <sup>2,3</sup> , Dr Eva Karltorp <sup>1,2</sup> , Jeremy Wales <sup>1,2</sup> .....	18
PP2.05 Notched cartilage with incus interposition ossiculoplasty combined with cavity obliteration - a novel approach : study of 50 cases.....	19
PP2.06 Neuroanatomical anomalies associated with the LAMM syndrome: Implications for ABI placement .....	20
Prof. MD PhD Johan Frijns <sup>1,2</sup> , MA Roos Geerders <sup>1</sup> , BA Eshter Scholing <sup>1</sup> , MD PhD Berit Verbist <sup>1</sup> , MD PhD Radboud Koot <sup>1</sup> , Prof MD PhD Martijn Malessy <sup>1</sup> , MSc Peter-Paul Boermans <sup>1</sup> , PhD Jeroen Briaire <sup>1</sup> .....	20
PP2.07 Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?.....	21
Froukje Cals <sup>1</sup> , Hylke vd Toom <sup>2</sup> , Mick Metselaar <sup>2</sup> , Anne v Linge <sup>2</sup> , Marc vd Schroeff <sup>2</sup> , RJ Pauw <sup>2</sup> .....	21
PP2.08 En Hamac tympanoplasty and canalplasty for optimal type 1 tympanoplasty outcomes.....	22
Dr Bob Lerut <sup>1</sup> , dr Rudi Kuhweide .....	22
PP2.09 External Auditory Canal Cholesteatoma: Clinical Presentation and Management of 22 cases	23
Kanu Saha <sup>1</sup> .....	23
PP2.10 Otopathology of Incomplete Partition Type III: Implications for Cochlear Implantation .....	24
Chloe Swords <sup>1</sup> , Prof Manohar Bance <sup>1</sup> , Dr Alicia Quesnel <sup>2</sup> .....	24
PP2.11 A novel classification system and surgical strategies of first branchial cleft anomalies .....	25
Dr. Yibo Zhang <sup>1</sup> , Dr. Dedi Kong <sup>1</sup> , Professor Chunfu Dai <sup>1</sup> .....	25
PP3.01 Success in Valsalva maneuver in each ear may vary in a patient due to differences in periluminal tissue pressures between the Eustachian tubes. ....	26
Prof Cuneyt M. Alper <sup>1,2</sup> , Miriam S. Teixeira <sup>3</sup> , J Douglas Swarts <sup>1</sup> .....	26
PP3.02 The vestibular implant: Results of the second generation device.....	27
Raymond van de Berg <sup>1</sup> , Nils Guinand <sup>2</sup> , Joost Stultiens <sup>1</sup> , Bernd Vermorken <sup>1</sup> , Benjamin Volpe <sup>1</sup> , Elke Devocht <sup>1</sup> , Elke Loos <sup>3</sup> , Marieke ten Hoor <sup>1</sup> , Michaela De Kock <sup>1</sup> , Stan van Boxel <sup>1</sup> , Helen Yuan <sup>1</sup> , Angelica Perez-Fornos <sup>2</sup> .....	27
PP3.03 A Multicenter, Single-arm, Objective Performance Criteria-controlled Clinical Study of the Safety and Efficacy of the Double-lumen Eustachian Tube Balloon Catheter .....	28
Prof. Yu Si <sup>1</sup> .....	28
PP3.04 Targeted temporal bone CT guidance for intratympanic steroid therapy .....	29
PP3.05 MRI-related artifacts after implantation of passive titanium implants and their influence on the detectability of cholesteatoma.....	30
Dr. Christoph J. Pfeiffer <sup>1</sup> , Dr. Alexander Kilgué <sup>1</sup> , Dr. Conrad Riemann <sup>1</sup> , Dr. Lars-Uwe Scholtz <sup>1</sup> , Dr. Dina Voeltz <sup>2</sup> , Prof. Dr. Hans-Björn Gehl <sup>3</sup> , PD Dr. Ingo Todt <sup>1</sup> .....	30
PP3.06 First clinical experience with a new device for the removal of cochlear schwannoma.....	31

Christoph Pfeiffer <sup>1</sup> , Conrad Riemann <sup>1</sup> , Rayoung Kim <sup>1</sup> , Lars Uwe Scholtz <sup>1</sup> , Ingo Todt <sup>1</sup> .....	31
PP3.07 High-quality educational surgery videos .....	32
Thijs Van Hees <sup>1,2</sup> , Dr Erik Hensen <sup>1,3</sup> .....	32
PP3.08 CSF gusher in cochlear implantation; our experience with 30 cases .....	33
Professor Ali Eftekharian <sup>1</sup> , Dr. Kourosh Eftekharian <sup>2</sup> , Dr. Maryam Amizadeh <sup>1</sup> , Dr. Mojgan Hosseinrezai Mahani <sup>1</sup> .....	33
PP3.09 Treatment response evaluation in necrotizing otitis externa using FDG-PET imaging .....	34
Dr Thadé Goderie <sup>1</sup> , Dr Robin Jansen <sup>1</sup> , Dr Pieter Kemp <sup>1</sup> , Dr Sanne Wiegers <sup>1</sup> , Dr Pim de Graaf <sup>1</sup> , Dr Roland Martens <sup>1</sup> , Dr Gerben Zwezerijnen <sup>1</sup> .....	34
PP3.10 Treatment of sinus thrombosis secondary to mastoiditis.....	35
Md Simon Kasper <sup>1</sup> , Dr. Froukje Cals <sup>1</sup> .....	35
PP3.12 The course of hearing loss in patients with a progressive vestibular schwannoma.....	36
Drs Kimberley S Koetsier, dr. Heiko Locher, dr. Radboud W. Koot, dr. Andel G L van der Mey, prof. Peter-Paul G van Benthem, prof. Jeroen C Jansen, dr. Erik F Hensen .....	36
PP3.13 Vestibular Function and Complaints in Patients with Untreated Unilateral Vestibular Schwannoma .....	37
Msc Constanza Fuentealba Bassaletti <sup>1</sup> , PhD Babette van Esch <sup>1</sup> , Msc Kenny van Lieshout <sup>2</sup> , PhD Heiko Locher <sup>1</sup> , PhD Jeroen Jansen <sup>1</sup> , PhD Radboud Koot <sup>1,3</sup> , PhD Peter Paul van Benthem <sup>1</sup> , PhD Erik Hensen <sup>1</sup> .....	37

# PP1.01 Clinical Cost Analysis between Transcutaneous and Percutaneous Bone Conduction Devices

Drs Tjerk Aukema<sup>1</sup>, Drs Emma Teunissen<sup>2</sup>, ir. dr. Arno Janssen<sup>2</sup>, prof. dr. Myrthe Hol<sup>1</sup>, prof. dr. Emmanuel Mylanus<sup>2</sup>

<sup>1</sup>Umcg, Groningen, Netherlands, <sup>2</sup>Radboudumc, Nijmegen, Netherlands

## Objectives

To compare and evaluate the total post-implantation costs between transcutaneous and percutaneous bone conduction devices.

## Methods

Retrospective data from 77 patients implanted in a tertiary referral centre with a pBCD (n=34), passive tBCD (tpasBCD; n=34) and active tBCD (tactBCD; n=9) and a reference group who underwent cochlear implantation (CI; n=34), were included in a clinical cost-analysis. Post-implantation costs were determined as the sum of consultation (medical and audiological) and additional (all post-operative care) costs. Median (cumulative) costs per device incurred for the different cohorts were compared at one, three and five years after implantation.

## Results

After five years the total post-implantation costs of the pBCD vs tpasBCD were not significantly different (€1550.7 [IQR 1174.6-2797.4] vs €2266.9 [IQR 1314.1-3535.3], p=0.185), nor was there a significant difference between pBCD vs tactBCD (€1550.7 [1174.6-2797.4] vs €1428.8 [1277.3-1760.4], p=0.550). Additional post-implantation costs were significantly highest in the tpasBCD cohort at all moments of follow-up.

## Conclusion

Total costs related to post-operative rehabilitation and treatments are comparable between percutaneous and (passive/active) transcutaneous BCDs up to five years after implantation. Complications related to passive transcutaneous bone conduction devices appeared significantly more expensive after implantation due to more frequent explantations.

## PP1.02 Intra- and post-operative experiences from 51 surgeries of a new active transcutaneous bone-anchored implant system.

Professor Dr. Myrthe K.S Hol<sup>1</sup>, Professor Emmanuel A.M. Mylanus<sup>2</sup>, Dr. Peter Monksfield<sup>3</sup>, Dr. Rupan Banga<sup>3</sup>, Dr James Tysome<sup>4</sup>, Professor Dr. Manohar Bance<sup>4</sup>, Professor Dr. Susan Arndt<sup>5</sup>, Professor Dr. Thomas Lenarz<sup>6</sup>, Dr. Rolf Salcher<sup>6</sup>, Dr. Kerstin Willenborg<sup>6</sup>, Dr. Nils Prenzler<sup>6</sup>

<sup>1</sup>University Medical Center Groningen, Groningen, The Netherlands, <sup>2</sup>Radboud University Medical Center, Nijmegen, The Netherlands, <sup>3</sup>Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, United Kingdom, <sup>4</sup>Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, United Kingdom, <sup>5</sup>Universitätsklinikum Freiburg, Freiburg, Germany, <sup>6</sup>Medizinische Hochschule Hannover, Hannover, Germany

### Objectives

Sentio (Oticon Medical AB, Sweden) is a new active transcutaneous bone-anchored implant system under evaluation for safety and performance in a multi-centre, single-arm, prospective, clinical investigation (Clinicaltrials.gov identifier NCT05166265). The objective of this abstract is to focus on intra- and post-operative variables from 51 surgeries, taking place between February 2022 and November 2023.

### Methods

The pre-market, pivotal clinical investigation follows individuals with conductive/mixed hearing losses or single sided deafness for a total period of 24-months after receiving an active transcutaneous bone-anchored implant. To date, recruitment has been completed and all 51 included participants have reached primary outcome assessment at 3 months, which is the first timepoint for analysing cohort data. Surgical variables include pre-operative planning, type of anaesthesia, type of surgical incision, and surgery time (first incision to last suture). A postoperative visit, 2 weeks after surgery was done to remove sutures and to assess wound healing, pain, and numbness.

### Results

The cohort represents an adult group with a mean age of 50 (range 24-77) years and with a distribution of the type of hearing loss of 51% conductive, 25% mixed, and 24% single sided deafness on the implanted side. Surgery duration is 58 min (range 23 - 85 min) and general anesthesia is used in most cases. In one case, surgery was done with local anesthesia only. Although pre-operative imaging techniques are part of clinical practice in some clinics, more than half of the surgeries was done without it. There was no case of aborted surgery due to insufficient bone thickness and/or unexpected anatomy. The most used incision type was a stepwise C-type (49%), but 'lazy S' type (33%) and other techniques (18%) were also observed. Surgical wounds heal within 2 weeks and the majority of patients report of low levels of pain and numbness. Performance and safety outcomes are reported elsewhere.

### Conclusion

The new active transcutaneous bone-anchored implant is small and minimal invasive to install. It can safely be implanted without preoperative imaging and surgery time could potentially be optimized to below 30 minutes depending on the individual patient's anatomy and prerequisites.

## PP1.03 Important factors for the outcomes of cochlear implantation in children

Prof Sanja Spiric<sup>1</sup>

<sup>1</sup>UKC Banja Luka, Banja Luka, Bosnia and Herzegovina

### **Objectives**

A perfect understanding of the relationship between receptive and expressive language in CI users is still not possible. We know that age at implantation, duration of CI use, unappropriated family environments, inner ear malformations, dysfunction of the synapses in an auditory pathway, or neurocognitive disorder are negatively associated with success in cochlear implantation.

### **Material and methods**

We analyzed speech perception abilities after cochlear implantation in children with prelingual and post-lingual, progressive hearing loss. Children with prelingual hearing loss were divided into 2 groups regarding the age at the implantation. For all participants, we applied a closed and open set for monosyllable words 12 months after implantation, an open set for polysyllable words in quiet and noise 24 and 36 months after surgery, and a sentence perception test 36 months postoperatively.

### **Results**

All participants showed significant improvement in speech perception abilities over time. The lowest speech perception score 1 year after surgery was observed in the group of children implanted between 3 and 5 years of age, but the difference was not significant. Children with post-lingual progressive hearing loss achieved significantly better speech perception scores in all tests two and three years after implantation (89-90,8%) compared with those implanted up to 2 years (73,6 - 81,2%) and between 3 and 5 years of age (63,2-74,8%).

### **Conclusion**

Duration of implant use significantly improves speech abilities in children implanted up to five years of age. Age at the implantation has a positive effect on speech abilities development especially if the listening is in demanding situations like in terms of background noise. Children implanted before two years of age have a gradual, continuous, and more natural improvement in speech abilities. Those who are implanted between three and five years of age expressed delay in listening skills two years postoperatively and significant improvement after this time. Continuance of implant use played a major role and significantly improved speech perception in CI children. The duration of auditory privation is better related to the CI outcomes than the age at which the patient was implanted.

# PP1.04 AC102 – Phase I Results and Phase II Initiation for a New Drug Candidate for the Treatment of Sudden Sensorineural Hearing Loss

Froukje Cals<sup>1</sup>, Sybren Robijn<sup>1</sup>, Reimar Schlingensliepen<sup>2</sup>, Christin Galetzka<sup>2</sup>, Cris Lanting<sup>1</sup>, Ronald Pennings<sup>1</sup>

<sup>1</sup>Radboudumc, Nijmegen, Nederland, <sup>2</sup>AudioCure Pharma GmbH, Berlin, Germany

## Background

Sudden sensorineural hearing loss (SSNHL) has a major socio-economic impact. Preclinically, this small molecule almost completely reversed noise-induced hearing loss, making it a promising drug candidate for the treatment of SSNHL.

## Material and method

In the completed phase I study, intratympanic administered AC102 was compared with placebo injections in healthy volunteers. The AC102 was used in increasing concentrations and volumes. End points were safety and tolerability of AC102, including assessment of audiological and vestibular function.

## Results

Treatment-emergent adverse events (TEAEs) were equally common in both treatment groups. Most TEAEs were mild and resolved within 1 week. TEAEs included discomfort, ear pain, minor bleeding at the injection site and short episodes of dizziness. The injection hole healed within 4 days at the latest. Short-term reversible conductive loss occurred in both groups, mainly in the higher frequencies. No serious adverse events (SAEs) were observed during the study. The plasma concentration of AC102 was dose dependent and decreased over the 24 hour observation period.

## Conclusion

AC102 was safe and well tolerated in healthy volunteers. It caused only mild and transient TEAEs and low systemic drug concentrations. AC102 is currently being evaluated in SSNHL patients in a randomized, blinded, two-arm phase II trial. Thirty European research centers include patients with moderate to severe idiopathic SSNHL. AC102 will be compared with standard treatment with oral steroids.

## Disclosure

This sponsor-initiated study is sponsored by AudioCure Pharma GmbH, Berlin, Germany.



## PP1.05 Long-term hearing results for otosclerosis patients receiving cochlear implants - Impact of facial nerve stimulation

Md, Phd Åsa Bonnard<sup>1,2</sup>, Med Stud Oskar Lindenfors<sup>2</sup>, Martin Eklöf<sup>1,2</sup>

<sup>1</sup>Karolinska Universitetssjukhuset, Stockholm, Sweden, <sup>2</sup>Karolinska Institutet, Stockholm, Sweden

### Introduction

Otosclerosis is a disease characterized by progressive bone transformation in the middle ear, primarily resulting in conductive hearing loss but potentially leading to mixed and sensorineural hearing loss.

Aims: This study aimed to investigate the long-term hearing outcomes following cochlear implantation in otosclerosis patients compared with a typical population receiving a cochlear implant (CI). Also, the impact of programming limitations related to facial nerve stimulation (FNS) was evaluated.

### Material and methods

The study included all otosclerosis patients who underwent CI surgery between 2003 and 2018 at the clinic, matched with a control group by age, implant type, preoperative hearing, and sex, with a minimum 5-year follow-up. The phonetically balanced words test (PB) was used to measure hearing outcomes and a mixed linear model was used to compare trends over time.

### Results

There were no significant differences in hearing outcomes at 5 years, with PB results of 48.7 vs 47 for cases and controls ( $p = 0.747$ ), or at last follow-up, 49.4 vs 44.3 ( $p = 0.317$ ). However, the mixed linear model showed a statistically significant improvement over time of 1.6 percentage points in the otosclerosis group compared to the control group ( $p = 0.005$ ). FNS incidence did not significantly differ between the groups ( $p = 0.693$ ) and had no significant impact on hearing outcomes ( $p = 0.620$ ).

### Conclusions

Despite the complexity of CI surgeries for otosclerosis patients, the long-term hearing outcomes for otosclerosis patients were comparable to the control group.

# PP1.06 Advancing Surgical Education and Skill Acquisition with the Exoscope for Cochlear Implantation in a Tertiary Hospital

Jona Minette Ligon<sup>1</sup>

<sup>1</sup>East Avenue Medical Center, Quezon City, Philippines

The exoscope has emerged as a transformative tool in modern medicine, revolutionizing the way surgeons visualize and perform intricate procedures such as cochlear implant. Compared to traditional microscopes, exoscopes offer enhanced flexibility, superior depth perception, and high-definition imaging capabilities making them assets across various surgical specialties. Their versatility renders them suitable for a wide range of surgical procedures and with training and education, their imaging capabilities allow trainees to observe procedures in real time or review recorded footages later on. Their design and ergonomic set up also minimize clutter in the operating room and provide surgeons with greater freedom of movement. In developing countries, the use of the exoscope is still limited, and advantages and ease of use are often faced with doubts, often leading to miss out on certain opportunities for enhancing surgery and teaching.

## **Objectives**

To demonstrate the efficacy of exoscope integration in otologic surgeries such as cochlear implantation and showcase the benefits of exoscope-assisted training in improving surgical skill acquisition and procedural proficiency. The paper also aims to explore the challenges and considerations associated with integrating exoscopes into surgical training.

## **Methods**

This is a case presentation of the experience of using the exoscope for cochlear implant surgery in a tertiary hospital. The traditional microscope has been the

## **Results**

The surgery was faster and safer with the exoscope, with the surgeon being able to clearly visualize the surgical field in high definition and with improved ergonomics, less fatigue and strain allowed for meticulous dissection and minimal tissue trauma. Also, the whole surgical team was able to appreciate the intricacies of cochlear implant surgery, and teaching the residents was more effective, enabling them to appreciate anatomy and landmarks as well as the surgical steps.

## **Conclusion**

The use of exoscopes enables surgeons to develop proficiency in intricate surgical techniques, allows for improved electrode placements and enhances overall procedural efficiency. Integration of exoscopes into surgical programs offers substantial benefits in enhancing surgical education and skill acquisition among young surgeons and trainees alike. Visualization of the anatomy and observance of proper surgical technique ensures optimized surgical outcomes and delivery of high-quality patient care.

## PP1.07 Long-term Results of Reverse Fixation Clip Technique on Electrode Migration Rates in a Large Cochlear Implant Cohort

Georg Schweizer<sup>1</sup>, Lina Maria Serna-Higuera<sup>2</sup>, Agnes Mühle<sup>1</sup>, Dr. med. Philipp Gamerdinger<sup>1</sup>, Dr. med. Thore Schade-Mann<sup>1</sup>, Prof. Dr. med. Dr. oec. Martin Holderried<sup>3</sup>, Dr. med. Steffen Paasch<sup>1</sup>, Prof. Dr. med. Hubert Löwenheim<sup>1</sup>, Dr. med. Anke Tropitzsch<sup>1,4,5</sup>

<sup>1</sup>Department of Otolaryngology - Head & Neck Surgery, University of Tübingen Medical Center, Tuebingen, Germany, <sup>2</sup>Department of Clinical Epidemiology and Applied Biostatistics, University of Tübingen Medical Center, Tuebingen, Germany, <sup>3</sup>Department of Medical Development and Quality Management, University Hospital Tübingen, Tuebingen, Germany, <sup>4</sup>Hearing Center, Department of Otolaryngology - Head & Neck Surgery, University of Tübingen Medical Center, Tuebingen, Germany, <sup>5</sup>Center for Rare Hearing Disorders, Centre for Rare Diseases, University of Tübingen, Tuebingen, Germany

### Objectives

Electrode migration is a common complication following cochlear implantation, particularly in straight electrodes, and often requires revision surgery. The use of a titanium electrode fixation clip was introduced more than 25 years ago. Here, we describe a novel reverse clip fixation technique and investigate the long-term results on electrode migration in a large cochlear implant cohort of more than 1000 patients.

### Methods

The use of a titanium electrode fixation clip with a double U configuration incorporating two fixation loops was first described in 1998 (Müller et al., 1998). According to the original description and the manufacturer's instructions, the opening of the bone loop is directed toward the middle ear. In the presented technique, the opening of the bone loop is directed toward the mastoid cavity and closed before the electrode insertion under the surgeon's direct view. A similar approach has been described recently (Morales-Puebla et al., 2024). To evaluate the effect of the fixation clip and the reverse placement technique on electrode migration rates and required revisions, we performed a retrospective analysis of 1052 cochlear implant cases with straight electrodes of a single manufacturer from 2011-2023. The years 2011-2016 served as a historical control group without the use of a fixation clip, whereas in the years 2017-2023, the fixation clip and the reverse placement technique were applied as an institutional standard/

### Results

A total of 1052 cases were included, with a median follow-up of 5.7 years. Overall, the clip was not applied in 461 (43.8%) of these cases, and in 591 (56.2%) cases the clip was applied. The cumulative incidence of electrode migration and revision surgery in the non-clip group at 1, 3, and 5 years was 0.2%, 0.7% and 1.1%, and in the clip group was 0%, 0%, and 0%, respectively (log-rank test = 0.051). No fixation clip-related complications were noted.

### Conclusion

The reverse fixation clip technique prevented electrode migration and revision surgery and did not notably increase the duration of surgery, require additional surgeon training, or cause intraoperative or postoperative complications.

## PP1.08 Audiological performance of the hearing contact lens Vibrosonic® alpha

Dr. Fritz Schneider<sup>1</sup>, Dr.-ing. Ernst Dalhoff<sup>1</sup>, Prof. Dr. Hubert Löwenheim<sup>1</sup>

<sup>1</sup>University of Tübingen Medical School, Department of Otorhinolaryngology – Head & Neck Surgery, Tübingen, Germany

### Objectives

The hearing lens “Vibrosonic® alpha” is a novel hearing device that directly stimulates the tympanic membrane by vibration. It consists of three components: First, a lens that is placed on the tympanic membrane; second, an ear-canal retainer connected to the lens by a flexible cable; third, a behind-the-ear module that is connected to the ear-canal retainer by a magnetic interface. Here, we investigate restoration of speech-recognition in the first 5 patients of a currently running clinical study.

### Methods

Aided speech recognition wearing the hearing lens “Vibrosonic® alpha” was compared with unaided speech recognition before application of the device using three speech-recognition tests: monosyllable discrimination in quiet (Word Recognition Score; WRS; German Freiburger Speech Test), 50% speech-recognition threshold of sentences in quiet (SRT50) and in noise (SNR50) (German version of the International Matrix Test; OLSA).

### Results

Mean un-aided pure-tone threshold was  $43 \pm 5$  dB HL (PTA4; 0.5, 1, 2, 4 kHz). Monosyllable discrimination was tested at the 50%-discrimination level of the unaided condition and improved on average by  $32\% \pm 13\%$ . Mean OLSA SRT50 in quiet improved by  $17 \pm 5$  dB in the first fitting from  $58 \pm 11$  dB SPL to  $40 \pm 1,7$  dB SPL. Mean SNR50 in noise improved by 0,9 dB in the first fitting. The maximum equivalent sound pressure was  $>100$  dB SPL and extends from  $<60$  Hz to 10 kHz.

### Conclusion

The audiological performance of the hearing lens device in this patient cohort is excellent. Monosyllable discrimination in quiet corresponds to the 75%-quartile of conventional hearing aids.

## PP1.09 A prospective multicentre European study investigating a one-step drill system (MONO) for bone anchored hearing procedures – Experience and outcomes at 1 year.

Mr Harry Powell<sup>1</sup>, Dr Tjerk Aukema, Miss Rupan Banga, Prof. dr. Myrthe Hol, Dr Dan Dupont Hougaard, Prof. dr. Emmanuel Mylanus, Dr Måns Eeg Olofsson, Dr Emma Teunissen, Mr James Tysome, Dr Sara Svensson

<sup>1</sup>St Thomas' Hearing implant Centre, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom

### Objectives

Surgical techniques for insertion of percutaneous bone anchored hearing systems (BAHS) have continuously improved, reducing surgical invasiveness and improving clinical outcomes. The latest advancement, MONO, is the newest technique for further improving and simplifying the surgery. With a novel parabolic drill design, the osteotomy is created with one single drilling step, in contrast to the three-step drilling sequence used conventionally. This study followed patients undergoing the MONO procedure for 12 months, to investigate safety and effectiveness of this BAHS.

### Methods

A prospective multicentre, multinational, single-arm, trial at seven centres in the UK, the Netherlands, Denmark and Sweden included 51 adult patients (52 implants) implanted using the MONO procedure (clinicaltrials.gov identifier NCT04606823). Implant stability and usage, soft tissue reactions, pain and numbness, post-operative events and sound processor usage were assessed at all follow-up visits. Hearing related quality of life was evaluated using the Glasgow Benefit Inventory (GBI).

### Results

The patients had a mean age of 57 years (range: 19–81), with 49% being over 65 years. Surgical time was short;  $10 \pm 5$  minutes with local anaesthesia used in 69% of cases. No severe intraoperative complications occurred. At 12 months, the sound processor was in daily use in 45 patients with an average usage time of 13 hours. Across all study visits, adverse skin reactions (Holgers  $\geq 2$ ) were seen in six patients but there were minor or no skin reactions in 97.4% of all post-operative visits. At 12 months there had been four implant failures; two traumatic failures and 2 spontaneous failures, one of which was surgery-related due to incomplete insertion of the fixture. Surgery was rated as quick and easy, with efficient bone removal. Firm initial pressure of the drill against the bone is recommended. The GBI analysis showed that 96% of the patients experienced an overall improvement in quality of life 3 months after surgery.

### Conclusion

The MONO surgical procedure for bone-anchored hearing system implantation provides a safe and efficient surgical technique for percutaneous implantation. Intra-operative and post-operative events reported were few and minor.

# PP1.10 ATOH-1 Gene Therapy for Regenerating Hair Cells and Restoring Auditory Function in Mice with Acquired Sensorineural Hearing Loss: A Meta Analysis and Bioinformatic Analysis of Preclinical Studies

Ahmad Saeed

<sup>1</sup>Z. K. Al-Sharif, , , <sup>1</sup>Nada Al-Awamleh, , , <sup>1</sup>Osama Younis, ,

## Background

Sensorineural hearing loss (SNHL) is the third leading cause of years lived with disability worldwide, affecting ~1.5 billion people. Acquired SNHL typically results from ototoxic damage to cochlear hair cells (HCs) and is often irreversible due to their limited regenerative ability. Currently, there is no definitive cure, but targeting the underlying pathology shows potential. Preclinical research has investigated transcription factors like ATOH-1, which can induce non-sensory supporting cells to transdifferentiate into HCs. Inner ear gene therapy, using viral vectors to deliver target genes, is a promising strategy in regenerative medicine. This meta-analysis is the first to confirm auditory function restoration through ATOH-1 gene therapy, supported by robust bioinformatics analysis.

## Methods

We conducted an integrative meta-analysis and bioinformatics methodology, starting with systematic literature search in PubMed, Web of Science and Embase databases. Random effects (DerSimonian and Laird) meta-analysis was conducted using OpenMeta-analyst to calculate the pooled effect size. We then corroborated our meta-analysis findings by conducting differential gene expression (DEG) analysis using iDEP.96 and the GEO dataset GSE127683.

## Results

Of 755 articles, 3 preclinical studies met the inclusion criteria. ATOH-1 gene therapy was associated with significantly lower Auditory Brainstem Response (ABR) (Mean difference = -3.755, CI: [-7.133, -0.377], p=0.029) (Overall heterogeneity:  $I^2=86.5\%$ ,  $P<0.001$ ), reflecting improved hearing function. DEG analysis revealed several genes that are important in hair cell differentiation and functioning including *Kcnma1*, *Myo6*, *Myo7a*, *Grxcr1*, *Gfi1*, *Otof*, and *Pouf43*. Moreover, Gene Set Enrichment Analysis (GSEA) revealed key upregulated pathways including inner ear development, auditory receptor cell differentiation, and sensory perception of mechanical stimulus and sounds.

## Conclusion

ATOH-1 gene therapy emerges as a promising strategy for treating acquired SNHL. However, further clinical trials are essential to confirm these preclinical results and advance towards a potential cure.

## PP2.01 Comparison of endoscopic cartilage myringoplasty with and without trimming perforation margins and epithelium of malleus handle for repairing subtotal perforation

[zhengcai Lou<sup>1</sup>](#)

<sup>1</sup>yiwu central hospital, Yiwu, China

### **Purpose of the study**

The trimming perforation margins and handle of malleus is considered the gold standard of myringoplasty for repairing chronic perforation involving the malleus. The objective of this study was to compare the graft success rate and hearing gain of endoscopic cartilage underlay myringoplasty with and without trimming perforation margins and epithelium of malleus handle for repairing subtotal perforation involving the malleus.

### **Materials and methods**

Chronic subtotal perforations undergoing endoscopic cartilage underlay myringoplasty were prospectively randomized to undergo trimming perforation margins and epithelium of malleus handle (trimming group) and no trimming group. The graft success rate, hearing improvement, and complications were evaluated at 12 months postoperatively.

### **Results**

In total, 53 patients with unilateral subtotal perforations were included (trimming group, 27; no trimming group, 26). All patients completed 12 months of follow-up. The mean operation time was  $41.2 \pm 1.8$  minutes in the trimming group and  $37.2 \pm 5.4$  minutes in the no trimming group, the difference was not significant ( $p=0.613$ ). The graft success rates were 96.3% (26/27) in the trimming group and 100.0% (26/26) in the no trimming group, the difference was significant ( $p=0.513$ ). In addition, no significant between-group differences were observed pre- ( $p=0.741$ ) or post- ( $p=0.687$ ) operative ABG values or mean ABG gain ( $p=0.659$ ). No middle ear and graft cholesteatoma were found during followup period in both groups.

### **Conclusion**

The graft success rate, hearing gain, and complications in endoscopic cartilage underlay myringoplasty with and without trimming perforation margins and epithelium of malleus handle were comparable, however, longer-term outcomes and risk of cholesteatoma, require further study.

## PP2.02 Comparison of long-term outcome of two endoscopic transtympanic myringoplasty for repairing large chronic perforations

[zhengcai Lou](#)<sup>1</sup>

<sup>1</sup>yiwu central hospital, Yiwu, China

### **Purpose of the study**

We compare the long-term efficacy of the over-underlay technique and transtympanic underlay alone technique using endoscopic cartilage-perichondrium myringoplasty for repairing large chronic perforations.

### **Materials and methods**

109 chronic large perforations with mucosal chronic otitis media were recruited and randomly allocated to endoscopic cartilage-perichondrium modified over-underlay myringoplasty (MOUM, n=55) (Fig.1) and endoscopic cartilage-perichondrium transtympanic underlay alone myringoplasty (TUAM, n=54). The graft success rate, hearing gain, mean operation time and postoperative complications were compared between the groups at 6 and 24 months.

### **Results**

In total, 99 patients were finally analysed. The graft success rates 6 months after surgery between MOUM and TUAM groups were not significantly different (100.0%vs 96.0%, $P = 0.484$ ). However, the MOUM group had a significantly higher success rate 24 months after surgery than the TUAM group (93.9% vs 76.0%,  $P= 0.028$ ). Additionally, postoperative ABG <10 dB was 73.5% patients in the MOUM group and 76.0% in the TUAM group, the difference wasn't significant ( $p = 0.953$ ). CT examination revealed well-pneumatized middle ears 24 months after surgery in both groups, and no middle ear cholesteatoma was observed (Fig.2).

### **Conclusion**

Endoscopic modified cartilage-perichondrium over-underlay myringoplasty is reliable and effective for repairing large perforations. It improves the long-term graft success rate compared to the endoscopic transtympanic underlay alone technique. The risk for iatrogenic cholesteatoma is minimal.



## PP2.03 Exome variant prioritization in a large cohort of hearing-impaired individuals indicates IKZF2 to be associated with hearing loss and guides future research for unsolved cases

[Hedwig M Velde](#)<sup>1,2</sup>, dr. Jeroen Smits<sup>3</sup>, Jaap Oostrik<sup>1</sup>, dr. Helger Yntema<sup>4</sup>, dr. Lonneke Haer-Wigman<sup>4</sup>, Prof. dr. Martijn Huynen<sup>5</sup>, Prof. dr. Ronald Pennings<sup>1</sup>, Prof. dr. Hannie Kremer<sup>1,4</sup>

<sup>1</sup>Radboud university medical center, Otorhinolaryngology, Nijmegen, Netherlands, <sup>2</sup>Radboud university medical center, Institute for Brain Cognition and Behaviour, Nijmegen, Netherlands, <sup>3</sup>University Medical Center Utrecht, Medical Genetics, Utrecht, Netherlands, <sup>4</sup>Radboud university medical center, Human Genetics, Nijmegen, Netherlands, <sup>5</sup>Radboud university medical center, Medical Biosciences, Nijmegen, Netherlands

### Objectives

Non-syndromic hereditary hearing loss (HL) is genetically highly heterogeneous, yet at least half of the cases remain unexplained in medical genetic testing. One of several reasons for this is that pathogenic variants can be located in “unknown” deafness genes. With a variant prioritization approach, we aimed to identify novel (candidate) genes for HL.

### Methods

Exome-wide sequencing data were collected for subjects with (presumed) genetic HL that remained unexplained in medical genetic testing (gene-panel analysis). Cases in group AD had presumed autosomal dominantly inherited HL (n=124) and in group AR, presumed autosomal recessive HL (n=337). Variants in known or candidate deafness genes (e.g. genes with preferential inner ear expression or mouse deafness genes) were prioritized based on predicted effects of the variants on the protein and on allele frequencies. Selected variants were then tested for their co-segregation with HL. For subjects with variants in known deafness genes suspected to be the cause of HL, the patients' phenotype (obtained from their Electronic Patient Record) was compared to that documented in the literature. If a variant in a candidate gene was suspected to be the cause of HL, the phenotype of the subjects and affected relatives was extensively assessed through the collection of audiometric data and audiovestibular questionnaires.

### Results

After rough filtering on allele frequency and predicted effect of the variants, a total of 61,180 variants in group AR and 61,180 in group AD were analyzed. Our most important finding was the association of IKZF2, a gene not previously identified as a “human deafness gene”, with dominantly inherited non-syndromic HL in three families. A total of nine affected subjects from these families were included in our study, ranging in age from 25 to 62. Their better ear PTA (0.5-4kHz) ranged from 29 (at age 25) to 75 dB HL (at age 56). All subjects reported progressive HL. There were no indications of vestibular symptoms.

### Conclusion

Variants of IKZF2 can underlie non-syndromic HL. The abundance of candidate genes for HL stresses the importance of including family members (e.g. for trio analysis) for variant prioritization.

## PP2.04 Progressive loss of sensitivity to electrical stimulation after cochlear implantation in X-linked POU3F4 incomplete partition 3 inner ear malformation deafness

Dr Martin Eklöf<sup>1,2</sup>, Dr Henrik Smeds<sup>2,3</sup>, Dr Eva Karltorp<sup>1,2</sup>, [Jeremy Wales](#)<sup>1,2</sup>

<sup>1</sup>Clinic for hearing implants, Karolinska University Hospital, Stockholm, Sweden, <sup>2</sup>CLINTEC, Karolinska Institute, Stockholm, Sweden, <sup>3</sup>Linköping University Hospital, Linköping, Sweden

### Objectives

Patients with X-linked incomplete partition type III (IP3) inner ear malformation deafness treated with cochlear implants exhibit higher 'Most Comfortable Loudness' (MCL) levels of stimulation and more electrode deactivation than patients with normal morphology. We endeavoured to analyze the progression of the MCL levels and electrode deactivation over time and assess those factors from electronic patient records (EPR) that could have led to deactivation. Furthermore, we aimed to assess whether speech perception was affected by a progressive loss of neural contact.

### Methods

All thirteen patients with the IP3 malformation in our clinical database were analyzed retrospectively with regards to impedance, stimulation levels, deactivated electrodes, and speech perception. A control group of patients with normal anatomy was included.

### Results

MCL levels increased over time by 2.5 charge units (qu) per year, which was not seen in the control group. Electrode deactivation was more common in IP3 malformation, and it was estimated that 25% of electrodes would be deactivated by 15 years of age. Impedance was stable but higher in the study population. Speech perception was lower in IP3 malformation generally and was correlated to the number of deactivated electrodes.

### Conclusion

Patients diagnosed with IP3 malformation deafness may suffer a greater risk of cochlear implant discontinuation compared to those with normal anatomy. A progressive loss of sensitivity to electrical stimulation may indicate a form of neural degradation in the abnormal cochlea. With time, patients in this group, even with cochlear implant technology, may be unable to perceive open discrimination of speech as they reach adulthood. This has clinical implications for the counselling of parents and the decision regarding hearing loss treatment and choice of communication mode.

## PP2.05 Notched cartilage with incus interposition ossiculoplasty combined with cavity obliteration - a novel approach : study of 50 cases.

Dr SEKHAR BANDYOPADHYAY<sup>1</sup>

<sup>1</sup>north Bengal Medical College And Hospital, Hospital, Siliguri, India

### Objectives

In chronic suppurative ear disease conductive hearing loss with erosion of ossicular chain pose serious challenge to the otologist . Austin-Kartush Type-A (Malleus and Stapes suprastructure are present with eroded Incus) constitute 60% of all ossicular chain defects in chronic suppurative ear disease. Various ossiculoplasty techniques have been developed till date. Modifications in ossiculoplasty with notched autologous conchal cartilage, incus interposition and cavity obliteration in selected cases can yield predictably good result.

### Methods

The present study includes patients who underwent ossiculoplasty for AUSTIN- KARTUSH type A ossicular defect ( M+, S+ , eroded long process of Incus) at North Bengal Medical College Hospital, Darjeeling, between 1st November 2017 to 31st October 2021. All other ossicular chain erosions e.g Austin -Kartush Type-B, C, D were excluded from the study. Preoperative HRCT temporal bone, Pure Tone Audiometry (Preoperative & postoperative) were done in all cases.

Canal wall down mastoidectomy with tympanoplasty was done in all cases. A small piece of autologous conchal cartilage is harvested (Thickness: 0.5mm, Diameter: 4mm). A central notch is fashioned with 0.6 mm diamond bur to accommodate the head of the stapes. The Incus is rotated and the body of incus is placed over the notched cartilage, to raise the height of the assembly up to the level of the horizontal semicircular canal. Big Temporalis fascia is harvested and placed between the anterior part of annulus , and the mastoid cavity, covering the neo ossicular chain. The tympanomeatal flap raised earlier ,is placed over the temporalis fascia. One inferiorly based ,another superiorly based flaps with periosteum and soft tissue around the mastoid cavity are used for cavity obliteration . Wide meatoplasty was done.

### RESULTS

N=50, Male 26, Female 24. Atticoantral disease:32 cases, Tubotympanic disease:18 cases. Preoperative average AB GAP : 29.3 dB, Postoperative average AB GAP 20.4 db. Significant improvement in post-operative air bone gap closure (  $p < 0.001$ ) was observed in notched cartilage with incus interposition ossiculoplasty .

### Conclusion

72% ossiculoplasty patients achieved post-operative AB GAP within 20 db. Ossiculoplasty with notched autologous cartilage, incus interposition and cavity obliteration is physiological , biocompatible and stable.

## PP2.06 Neuroanatomical anomalies associated with the LAMM syndrome: Implications for ABI placement

Prof. MD PhD Johan Frijns<sup>1,2</sup>, MA Roos Geerders<sup>1</sup>, BA Eshter Scholing<sup>1</sup>, MD PhD Berit Verbist<sup>1</sup>, MD PhD Radboud Koot<sup>1</sup>, Prof MD PhD Martijn Malesy<sup>1</sup>, MSc Peter-Paul Boermans<sup>1</sup>, PhD Jeroen Briaire<sup>1</sup>

<sup>1</sup>Leiden University Medical Center, Leiden, Netherlands, <sup>2</sup>Delft University of Technology, Delft, Netherlands

### Objectives

To illustrate how careful observation of the outcomes of auditory brainstem implants (ABIs) can uncover structural abnormalities of the auditory brainstem associated with a specific disorder, in this case the LAMM (Labyrinthine Aplasia, Microtia and Microdontia) syndrome, and to demonstrate its clinical impact.

### Methods

Three MedEl Synchrony Pin ABIs were placed in two congenitally deaf male siblings with the same compound heterozygotic pathogenic mutations in the FGF3 gene, associated with the LAMM syndrome. Both children had bilateral cochleovestibular aplasia, precluding cochlear implantation, and microdontia, but just minor resp. unilateral microtia. Pre-operative workup included both CT and MRI scans. Intra-operative eABR recordings were performed with the placing and the actual electrode. Oral speech and language development was monitored with the Dutch version of the IT-MAIS questionnaire.

### Results

The elder brother received an ABI at the age of 14 months, with very limited auditory responses on all four positions of the implant tested. During the ABI-surgery of the younger subject (aged 13 months) excellent auditory responses could be obtained when the electrode array was placed considerably more caudally and more medially than standard, in line with the observation that the foramen of Luschka was located more caudally. In view of this observation and the good auditory development of the latter child, it was decided to give the older child a contralateral ABI (at the age of 60 months), even though we were not able to visualize the abnormal position of foramen of Luschka on the MRI in any of the children. Again, during surgery, it turned out that the anatomy of the brainstem was abnormal with a more caudal location of the foramen of Luschka and the cochlear nucleus, and with his second implant this child is showing good progress with his auditory development.

### Conclusion

One should be aware of anatomical differences at the level of the brainstem when placing ABI in children with genetic disorders. This also underpins the need of a multidisciplinary approach with closely collaborating team members and good family guidance when diagnosing and treating children with rare deafness.

## PP2.07 Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?

Froukje Cals<sup>1</sup>, Hylke vd Toom<sup>2</sup>, Mick Metselaar<sup>2</sup>, Anne v Linge<sup>2</sup>, Marc vd Schroeff<sup>2</sup>, RJ Pauw<sup>2</sup>

<sup>1</sup>Radboudumc, Nijmegen, Nederland, <sup>2</sup>Erasmus MC, Rotterdam, Nederland

### Introduction

This study aims to describe the occurrence of postoperative complications related to cholesteatoma surgery and to determine factors influencing the most common complication, i.e. postoperative surgical site infection (SSI) in cases with and without mastoid obliteration.

### Materials and methods

Retrospective analyses were performed on surgically treated cholesteatomas in our hospital between 2013 and 2019. Patient characteristics, peri- and postoperative management and complications were reviewed. The cases were divided into two groups based on whether mastoid obliteration was performed or not.

### Results

A total of 336 cholesteatoma operations were performed, of which 248 cases received mastoid obliteration. In total 21 complications were observed, of which SSI was the most common (15/21). No difference in occurrence of any postoperative complication was seen between the obliteration and no-obliteration group ( $p = 0.798$ ), especially not in the number of SSI ( $p = 0.520$ ). Perioperative and/or postoperative prophylactic antibiotics were not associated to the development of an SSI in both groups. In the no-obliteration group a younger age ( $p = 0.015$ ), as well as primary surgery ( $p = 0.022$ ) increased the risk for SSI. In the obliteration group the use of bioactive glass (BAG) S53P4 was identified as independent predictor of SSI ( $p = 0.008$ , OR 5.940).

### Discussion

SSI is the most common postoperative complication in cholesteatoma surgery. The causes of SSI are multifactorial, therefore further prospective research is needed to answer which factors can prevent the development of an SSI in cholesteatoma surgery.

## PP2.08 En Hamac tympanoplasty and canalplasty for optimal type 1 tympanoplasty outcomes

[Dr Bob Lerut<sup>1</sup>](#), dr Rudi Kuhweide

<sup>1</sup>Az Sint Jan Brugge, Brugge, Belgium

### **Objective**

Multiple tympanoplasty techniques have been developed with numerous differences in grafting and approach. This study aimed to improve type 1 tympanoplasty outcomes by using the 'en hamac' technique as well as performing a complete canalplasty for anterior perforations. Method. A retrospective review was performed using the prospective Otology-Neurotology Database tool for otological surgery. All primary type 1 tympanoplasty cases performed for tympanic membrane perforations from 2010 to 2016 were selected for analysis, all performed by one author. Minimal clinical and audiometric follow up was 18 months.

### **Results**

Tympanic membrane perforation closure was achieved in 62 of the patients (96.88 per cent). None of the en hamac cases had residual or recurrent perforation ( $p = 0.02$ ). The mean remaining air-bone gap was 8.50 dB. The remaining air-bone gap was less than 10 dB in 72.55 per cent, 10–20 dB in 25.49 per cent and more than 20 dB in 1.96 per cent.

### **Conclusion**

Using the en hamac technique for anterior perforations as well as systematically performing a complete canalplasty provides multiple surgical advantages with excellent post-operative results.

## PP2.09 External Auditory Canal Cholesteatoma: Clinical Presentation and Management of 22 cases

Kanu Saha<sup>1</sup>

<sup>1</sup>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

### Objectives

To evaluate the clinical presentation, management, and outcome of primary and secondary external auditory canal cholesteatoma (EACC).

### Methods

Twenty-two consecutive cases of external auditory canal cholesteatoma (seven primary EACC and fifteen secondary EACC) were retrospectively reviewed from January 2012 to March 2024. An online-based Ear Surgery Data software was used for data entry. Pre-operative, per-operative, and post-operative Otoendoscopic or Microscopic findings were documented with photographs and a video recording system. In each case, the clinical data concerning age, sex, presenting symptoms, previous history, lesion side, EACC localization, staging, surgical treatment, outcome, and recurrence were reviewed. Audiological and radiological data (HRCT temporal bone) were documented and analyzed for each patient. The cases of EACC were staged according to the staging system of Naim et al..

### Results

The presenting age range was 5-55 years, with a mean age of 25. Otorrhoea (100%) was the predominant symptom in primary EACC and otalgia and hearing loss were the predominant symptoms in secondary EACC. The most common lesion site in primary EACC was the posterior wall (71.43%), followed by the inferior wall (28.57%). On the other hand, multiple wall involvement was noticed in all (100%) secondary EACC. All cases required surgical intervention. Among seven primary EACC cases, six cases were managed by canal wall down mastoidectomy and one case by canaloplasty and tympanoplasty. Surgical procedures applied in fifteen secondary EACC cases included canal wall down mastoidectomy in 4 cases, subtotal petrosectomy (STP) in 3 cases, canalplasty in 5 cases, removal of foreign body and conservative treatment in 2 cases, and excision of mass and canaloplasty in one case.

### Conclusions

With a wide age range of presentation, old age may not be a predisposing factor in primary EACC. Instead of the inferior wall, posterior wall involvement in primary EACC explains the extension of the lesion into the mastoid in stage IV disease. An early stage of primary EACC (stages I and II) can be managed with the conservative approach. The advanced stages of primary and most cases of secondary EACC require various surgical methods, depending on the stage.

## PP2.10 Otopathology of Incomplete Partition Type III: Implications for Cochlear Implantation

Chloe Swords<sup>1</sup>, Prof Manohar Bance<sup>1</sup>, Dr Alicia Quesnel<sup>2</sup>

<sup>1</sup>Cambridge University Hospitals, Cambridge, United Kingdom, <sup>2</sup>Massachusetts Eye and Ear Infirmary, Boston, United States

### Objectives

To describe the histopathology of Incomplete Partition Type III (IP-III) and consider it in the context of cochlear implant surgery.

### Methods

The right temporal bone of an infant with otopalatodigital syndrome was fixed, decalcified, embedded, and sectioned at 20µm intervals. Every 10th section was stained with hematoxylin and eosin, and digitised. The otic capsule, scalae, and Rosenthal's canal were reconstructed in 3D in Amira. Spiral ganglion neurons (SGN) were counted.

### Results

2D inspection and 3D reconstruction revealed incomplete separation of the basal turn of the cochlea from the internal auditory canal (IAC), with the enlarged scala vestibuli (SV) in continuum with the IAC and subarachnoid space. The height of the basal turn scala tympani (ST) was less than SV (round window: 0.64mm vs 1.54mm; 180° 0.41mm vs 1.23mm; 360° 0.53mm vs 0.97mm). The lamina cribrosa was absent between the basal turn of the cochlea and IAC fundus. The interscalar septum between the 1st and 2nd turns was thick medially but missing laterally. There was no cochlear aqueduct. Quantification of SGNs on histologic sections revealed a reduced population (17% of normal for age). Rosenthal's canal was hypoplastic in the basal turn but normal beyond 360 degrees.

### Conclusions

To our knowledge, this is the first identified histopathological sample of IP-III, and illustrates the morphological basis for intraoperative gusher. This analysis is relevant for cochlear implant candidacy. The anatomical findings of an unpredictable location of SGN in the basal turn and the reduced ST height, means middle turn cochleostomy to reach the viable SGN population or SV insertion could be considered.



## PP2.11 A novel classification system and surgical strategies of first branchial cleft anomalies

[Dr. Yibo Zhang](#)<sup>1</sup>, [Dr. Dedi Kong](#)<sup>1</sup>, [Professor Chunfu Dai](#)<sup>1</sup>

<sup>1</sup>Eye,ear,nose & Throat Hospital Of Fudan University, Shanghai, China

### **Objective**

To define a novel classification of FBCAs based on the relationship between lesions and the facial nerve in term of radiographic imaging findings and to introduce the corresponding surgical managements.

### **Methods**

The clinical data were retrospectively reviewed. Novel classification was proposed according to the head neck MRI findings and surgical records. FBCAs limited in the cartilaginous segment of external auditory canal (EAC) or superficial parotid gland capsule were classified as type A. Lesions close to the FN and(or) involved into the parotid gland with no scar formation and no previous parotidectomy were classified as type B. FBCAs adhered to the FN and(or) invaded the parotid gland with scar formation due to previous surgery were classified as type C. Appropriate surgery approaches was also described which was correlated with classification.

### **Results**

Fifty-one patients were included, and one patient suffered from bilateral lesions. Thirty-one, twelve and nine lesions were classified as type A, type B and type C FBCAs respectively. One type A patient (1.92%) suffered from recurrence during follow-up. Temporary facial palsy (House-Brackmann II) was identified in 2 type C patients (3.85%) after surgery and recovered to normal within 2 months. One type B patient (1.92%) suffered from facial paralysis due to the FN injury and underwent facial nerve graft simultaneously. No patients with type C complained of hearing loss postoperatively.

### **Conclusion**

This novel classification clearly illustrates definitely relationship between lesion and the facial nerve and appropriate surgical strategies were proposed based on the novel classification.

## PP3.01 Success in Valsalva maneuver in each ear may vary in a patient due to differences in peri-luminal tissue pressures between the Eustachian tubes.

Prof Cuneyt M. Alper<sup>1,2</sup>, Miriam S. Teixeira<sup>3</sup>, J Douglas Swarts<sup>1</sup>

<sup>1</sup>Department of Otolaryngology, University of Pittsburgh, Pittsburgh, United States, <sup>2</sup>Pediatric Otolaryngology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, United States, <sup>3</sup>Arnot Ogden Medical Center, Elmira, United States

### Objectives

The Valsalva maneuver (VM) increases nasopharyngeal pressures (NPP) to open the Eustachian tube (ET). The inability to perform VM has been considered a marker for ET function (ETF). Success in VM is determined by the achieved NPP and the physical properties of the ET. A study is conducted to assess subjects during VM, detect successful ET openings, and the passive functional properties of each ET.

### Methods

A total of 23 subjects with history of ET dysfunction (ETD), 8 female 15 male, between ages 8-60 (average: 17.1+11.3), with bilateral non-intact tympanic membranes were evaluated in an ETD center, had recordings of the maximal NPP (maxNPP) during VM on each side and ability to open the ET on each side was recorded. Each ear of the subjects then underwent forced response test, to assess the passive functional properties of the ET by the measuring the opening pressure (OP), closing pressure (CP), and pressure during steady state air flow (PSS). Results between ears of the same subject and ears with and without successful VM were compared.

### Results

Average differences between ears with lower measurement compared to the higher, in each subject for OP, CP, and PSS were 140.7+125 daPa (33.1+20.4% less), 48.5+42.3 daPa (48.6+27.4% less) and 96.5+80.3 daPa (38.9+22.6% less) respectively. A total of 18 ears (39.1%) of 12 subjects (6 bilateral, 6 unilateral) successfully opened their ET during VM (ear group VM-S) compared to 28 that failed (ear group VM-F). The average maxNPP for the VM-S and VM-F ears were 652.3+197.8 daPa and 390.1+129.5 daPa respectively. For the VM-S and VM-F ears, the average OP was 307.8+133 daPa and 353.8+176.2 daPa, and the CP was 67.6+55.8 daPa and 88.4+76.6 daPa respectively. For the VM-S and VM-F ears, average PSS was 166.3+99.6 daPa and 215.8+125.8 daPa respectively.

### Conclusions

Successful VM is associated with the maxNPP. Although a patient achieves similar maxNPP when performing VM, success may be different on each side, determined by the passive functional properties of ETs, resistance from the peri-luminal tissue pressures. This variability requires attention to ear specific assessments and indication for balloon dilation treatment.

## PP3.02 The vestibular implant: Results of the second generation device

Raymond van de Berg<sup>1</sup>, Nils Guinand<sup>2</sup>, Joost Stultiens<sup>1</sup>, Bernd Vermorcken<sup>1</sup>, Benjamin Volpe<sup>1</sup>, Elke Devocht<sup>1</sup>, Elke Loos<sup>3</sup>, Marieke ten Hoor<sup>1</sup>, Michaela De Kock<sup>1</sup>, Stan van Boxel<sup>1</sup>, Helen Yuan<sup>1</sup>, Angelica Perez-Fornos<sup>2</sup>

<sup>1</sup>Maastricht University Medical Center, Maastricht, Nederland, <sup>2</sup>Geneve University Hospital, Geneva, Switzerland, <sup>3</sup>Leuven University Hospital, Leuven, Belgium

### Background

Patients with bilateral vestibulopathy suffer from a variety of complaints, such as oscillopsia, imbalance and cognitive complaints. Individually, this leads to a decreased quality of life and on a socio-economic level, the burden is high. The vestibular implant was designed to restore the vestibular deficit by providing motion information through implanted electrodes. It was previously demonstrated that this neuroprosthesis is feasible, as it can (partially) restore the reflexes such as the vestibulo-ocular reflex and vestibulo-colic reflex, as well as functional improvements on dynamic visual acuity, posture, gait and quality of life.

### Methods

Additionally, 9 patients with bilateral vestibulopathy were implanted with the second generation vestibulo-cochlear implant using peroperative imaging techniques. Vestibular reflexes, perceptual responses and functional outcome measures were tested.

### Results

In the patients receiving the second generation vestibulo-cochlear implant, all electrodes were surgically placed close to the ampullary nerve. It was possible to electrically elicit a vestibulo-ocular reflex in all but one patient. Obtained eye velocities were significantly higher with this second generation device. Different types of perception were evoked in all patients, and functional tests such as dynamic visual acuity and vHIT showed improvement. It was demonstrated that vestibulo-cochlear implant fitting can significantly change Video Head Impulse Test results.

### Conclusion

The latest vestibulocochlear implant can improve vestibular reflexes, vestibular perception, as well as functional tests. This shows its feasibility as a clinical useful device in the near future.

# PP3.03 A Multicenter, Single-arm, Objective Performance Criteria-controlled Clinical Study of the Safety and Efficacy of the Double-lumen Eustachian Tube Balloon Catheter

[Prof. Yu Si<sup>1</sup>](#)

<sup>1</sup>Sun Yat-sen Memorial Hospital, Guangzhou, China

## Objectives

To prospectively evaluate the technical efficacy and safety of the double-lumen Eustachian tube (ET) balloon catheter in patients with ET dysfunction.

## Methods

Patients who were diagnosed with ET dysfunction and needed balloon eustachian tuboplasty (BET) were prospectively enrolled. A double-lumen ET balloon catheter was used to dilate the ET and inject medicine. Efficacy results were assessed by the injection channel patency (ICP) rate, the injection reached the expected site (IRES) rate, and the improvement in Eustachian Tube function was evaluated by the 7-item Eustachian Tube Dysfunction Questionnaire (ETDQ-7) score. Safety results were assessed in terms of adverse events and device defects.

## Results

BET was successfully attempted in 87 patients from April 2022 to August 2022 at two academic medical centers in China (01, 02). The ICP rate was 100%, and the IRES rate was 88.51%. The overall ETDQ-7 score was significantly reduced ( $P < 0.001$ ) postsurgically at both centers. There were no major complications or device defects.

## Conclusion

The double-lumen ET balloon catheter is technically effective and safe for the treatment of ET dysfunction.

## PP3.04 Targeted temporal bone CT guidance for intratympanic steroid therapy

Prof. Yu Si<sup>1</sup>

<sup>1</sup>Sun Yat-sen Memorial Hospital, Guangzhou, China

### Objectives

To evaluate the radiological anatomy at the round window region and to develop and validate a predictive nomogram for hearing recovery in sudden sensorineural hearing loss (SSNHL).

### Methods

Thirty-nine patients diagnosed with severe or profound SSNHL and firstly hospitalized between January 2020 and December 2023 were enrolled in this retrospective study. All participants received corticosteroid impulse and intratympanic injection. The anatomical characteristics at RW region were summarized by temporal HRCT imaging. The pre- and post-treatment hearing thresholds were compared to evaluate the therapeutic effect. Additionally, the implication of radiological anatomy in the hearing outcome was investigated by univariate logistic regression analysis.

A total of 130 patients with SSNHL who firstly underwent intratympanic corticosteroids were enrolled into this research and randomly divided into

the development and validation group. The clinical and audiological data of patients were summarized, and the anatomical characteristics at RW region were evaluated by temporal HRCT imaging. A nomogram was constructed based on radiological signature and clinical risk factors to predict the probability of hearing recovery, then internally and cross validated by the development and validation cohort. The discriminatory ability of the nomogram was estimated by AUC (Area Under the receiver operating characteristic Curve), calibration curve and decision curve analysis.

### Results

In total of 91 patients in the training cohort and 39 patients in the validation cohort were enrolled. Eight variables (age, course, PTA, RWNV, entrance, depth, morphology, and pneumatization) were identified in the hearing recovery prediction model, in which, the presence of RWNV, the narrow RWN, and the deep RWN were independent poor prognostic factors for hearing recovery after local administration. The internal and cross validation of Receiver Operating Characteristic (ROC) curve was statistically significant (AUC = 0.723 and 0.786, respectively). The calibration curve showed good agreement between the prediction and actual observation.

### Conclusion

A nomogram based on radiological signature and clinical risk factors could intuitively and accurately predict the hearing outcome in patients with SSNHL undergoing local administration.

## PP3.05 MRI-related artifacts after implantation of passive titanium implants and their influence on the detectability of cholesteatoma

[Dr. Christoph J. Pfeiffer](#)<sup>1</sup>, Dr. Alexander Kilgué<sup>1</sup>, Dr. Conrad Riemann<sup>1</sup>, Dr. Lars-Uwe Scholtz<sup>1</sup>, Dr. Dina Voeltz<sup>2</sup>, Prof. Dr. Hans-Björn Gehl<sup>3</sup>, PD Dr. Ingo Todt<sup>1</sup>

<sup>1</sup>Department of Otolaryngology, Head And Neck Surgery, Medical School OWL, Bielefeld University, Klinikum Bielefeld Mitte, Bielefeld, Germany, <sup>2</sup>Biostatistics and Medical Biometrics, Medical School OWL, Bielefeld University, Bielefeld, Germany, <sup>3</sup>Department of Radiology, Medical School OWL, Bielefeld University, Klinikum Bielefeld Mitte, Bielefeld, Germany

### Objectives

Surgical removal is the treatment of choice for a cholesteatoma. Depending on the cholesteatoma an affection of the ossicular chain or the skull base can occur. Titanium implants (prostheses, meshes) can be used to restore sound transmission and to cover larger defects of the skull base. After the surgery, recurrence and residual control are necessary. This can be done using second-look surgery or an MRI examination with a non-EPI DWI sequence. Like other metal implants, artifacts may occur in the image due to the titanium used. Assessing the limitation of cholesteatoma detection utilizing non-EPI DWI sequence-generated MRI artifacts due to the titanium foreign material (prosthesis, mesh) is of central importance. This study aimed to estimate titan implant-related MRI artifacts after cholesteatoma surgery.

### Material and methods

MRI examinations after cholesteatoma surgery and one-stage implantation of a PORP, TORP, or titanium mesh were investigated by different sequences. Other reconstructions were excluded. The size of the artifacts was measured, and the mean artifact sizes of the respective prosthesis types were compared.

### Results

28 MRI examinations could be included. Artifacts occurred in all titanium implants. We observed a correlation between prosthesis/ mesh and artifact size. All subsequent second-look surgeries confirmed the MRI examinations according to a positive control for the presence of a cholesteatoma.

### Discussion and conclusion

The cholesteatoma size influences the detectability of a recurrence in the presence of titanium material. The prosthesis size influences the size of the artifact in the image.

## PP3.06 First clinical experience with a new device for the removal of cochlear schwannoma

Christoph Pfeiffer<sup>1</sup>, Conrad Riemann<sup>1</sup>, Rayoung Kim<sup>1</sup>, Lars Uwe Scholtz<sup>1</sup>, [Ingo Todt<sup>1</sup>](#)

<sup>1</sup>Bielefeld University, Bielefeld, Germany

### Background

In most cases, intra-labyrinthine schwannoma (ILS) occurs in patients with unilateral hearing deterioration or neurofibromatosis type II (NF II). The pattern of localization of these tumors is various but affects mostly the cochlea. Extirpation of the ILS, if hidden by the cochlea modiolus, is difficult under the aspect of complete removal. Therefore, a tissue removal device (TRD) was designed and tested in temporal bones. The principle of handling the new device is a pushing and pipe cleaner handling inside the cochlea. This present study aimed to describe the first in vivo experience with the newly developed TRD for removing cochlear intra-labyrinthine schwannoma.

### Methods

In three patients, the TRD was used for the tumor removal of ILS. In two patients with a cochlear schwannoma in combination with a cochlea implantation and one patient suffering from NF II, a cochlear schwannoma was removed with the TRD. The access was performed with a posterior tympanotomy, an enlarged round window approach, and an additional second-turn access. The device was inserted and extracted gradually from the second turn access until the rings were visible in the second turn access. By pushing and pipe cleaner handling, the tumors were removed. An MRI control was performed on the day postoperatively with a T1 GAD sequence.

### Results

Tumor removal with the TRD was performed in a 15-minute procedure. MRI control confirmed a complete removal on the postoperative day in all cases.

### Conclusion

In vivo handling of the device confirmed a straightforward handling for tumor removal. MRI scanning showed a complete removal of the tumor by the TRD.

## PP3.07 High-quality educational surgery videos

Thijs Van Hees<sup>1,2</sup>, Dr Erik Hensen<sup>1,3</sup>

<sup>1</sup>Eardrop Foundation, Zeist, The Netherlands, <sup>2</sup>Alrijne hospital, Leiderdorp, The Netherlands, <sup>3</sup>Leiden University Medical Center (LUMC), Leiden, The Netherlands

### **Objectives**

Eardrop Foundation (Netherlands) trains local professionals in ear and hearing care in East Africa. A new development in spreading ear surgery know-how and skills is the creation of high-quality educational surgery videos, made available worldwide.

### **Methods**

In co-creation with Incision, a platform that develops and distributes high-quality educational surgery videos, Eardrop Foundation developed oto-surgical videos, using cadaver specimens in a skills lab.

### **Results**

Six instructional oto-surgical videos have been developed with high educational value, and made accessible for free worldwide (except in the Netherlands) through a registration link. This link is shared with partners in East African countries and the Global OHNS Initiative. The videos proved very useful additions to temporal bone dissection courses, with the added benefit of lasting accessibility at any desired time.

### **Conclusion**

Educational oto-surgical videos are a valuable addition to the existing educational palette. The videos were developed by the Eardrop Foundation for its projects in East Africa, but at the same time have the added value of being available free of charge worldwide. The next step is creating instructional videos of oto-surgical procedures on patients. Sharing high-quality instructional videos worldwide elevates the level of surgical education and saves colleagues costly and time-consuming creation processes.



## PP3.08 CSF gusher in cochlear implantation; our experience with 30 cases

Professor Ali Eftekharian<sup>1</sup>, Dr. Kourosh Eftekharian<sup>2</sup>, Dr. Maryam Amizadeh<sup>1</sup>, Dr. Mojgan Hosseinrezai Mahani<sup>1</sup>

<sup>1</sup>Shahid Beheshti University Of Medical Sciences, Tehran, Iran, <sup>2</sup>Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Stanford University, Palo Alto , USA

### Objectives

The incidence of cerebrospinal fluid (CSF) gusher in cochlear implantation is reported to be 1-5% in large series. Watertight sealing around the cochlear implant array is essential to lessen the risk for further CSF leakage, which may lead to a potential hazard for meningitis. The aim of this study is to share our experience of CSF gusher in cochlear implantation and discuss our management strategy.

### Methods

We evaluated demographic, radiological, and surgical data from 1482 consecutive cochlear implant recipients of our cochlear implant center, including children and adults, who experienced CSF gushers during surgery. We focused on cases with profuse CSF gushers and excluded those with oozing or pulsatile perilymph. Additionally, we conducted a literature review.

### Results

Among the cases, 30 (2.02%) experienced CSF gushers. Two patients (6.7%) were post-lingually deafened adults and the rest (93.3%) were children with congenital deafness. Twenty four patients (80%) had various types of inner ear malformation and the most common one was incomplete partition type I (61.5%).

Four patients (13.3%) had no predictive preoperative imaging and no history of CSF gusher. CSF gushers were controlled in all patients by our technique of packing at the electrode entrance site with no additional measures. The presenter will describe his technique in detail.

### Conclusion

Surgeons should always be prepared to manage CSF gushers, even in unpredictable situations. Management of CSF gushers can be mainly performed at the initial stage of surgery by precise watertight sealing of the electrode entrance site, and further nonsurgical or surgical measures are rarely required.

## PP3.09 Treatment response evaluation in necrotizing otitis externa using FDG-PET imaging

Dr Thadé Goderie<sup>1</sup>, Dr Robin Jansen<sup>1</sup>, Dr Pieter Kemp<sup>1</sup>, Dr Sanne Wiegers<sup>1</sup>, Dr Pim de Graaf<sup>1</sup>, Dr Roland Martens<sup>1</sup>, Dr Gerben Zwezerijnen<sup>1</sup>

<sup>1</sup>Amsterdam Umc, Amsterdam, Netherlands

### Objectives

Necrotizing otitis externa (NOE) poses significant clinical challenges due to its rarity and potential life-threatening complications. Treatment includes multiple weeks of systemic antibiotics and management of comorbidities. However, evaluating treatment response presents challenges, sometimes due to the difficult differentiation between sterile inflammation and active infection on FDG-PET. This study aims to identify FDG-PET imaging features aiding in the accurate determination of treatment response in NOE, aiming to enhance patient outcomes and refine clinical management strategies.

### Methods

In a single-center retrospective cohort study approved by the Institutional Review Board of the VU University Medical Center, patients diagnosed with Necrotizing Otitis Externa (NOE) between 2011 and 2022 were analyzed. NOE criteria included otalgia, otorrhea, granulation, and radiological features consistent with osteomyelitis. Data collection involved patient demographics, comorbidities, microbiological results, and treatment outcomes. FDG-PET parameters were derived from manually delineated regions of interests, and were evaluated on both pre- and post-treatment scans. Statistical analyses were conducted, including Mann-Whitney U tests and determination of optimal cutoff values for predicting recurrences.

### Results

This study comprised 20 NOE patients, with 5 experiencing recurrent disease. Post-treatment FDG-PET parameters, particularly maximal standardized uptake value (SUV Max) and peak standardized uptake value (SUV Peak), were significantly higher in recurrent cases. Both parameters demonstrated 'very good' discrimination ability in predicting recurrence, with optimal cutoffs yielding 100% sensitivity and 67% specificity. Other parameters including SUV mean, total lesion glycolysis, did not yield significant results, neither did the calculated difference in uptake between post-treatment and pre-treatment scan.

### Conclusions

SUV-Peak on FDG-PET may be an adequate parameter for response evaluation of necrotizing otitis externa distinguishing patients at risk for recurrent disease which may necessitate prolonged treatment from patients without risk for recurrent disease permitting safe treatment cessation.

## PP3.10 Treatment of sinus thrombosis secondary to mastoiditis.

Md Simon Kasper<sup>1</sup>, Dr. Froukje Cals<sup>1</sup>

<sup>1</sup>Ent Department Radboudumc, Nijmegen, Nederland

### **Objective**

To evaluate the need for surgical intervention versus conservative treatment in sinus thrombosis (ST) secondary to mastoiditis.

### **Methods**

A retrospective case series was analyzed. Patients with mastoiditis and sinus thrombosis that received a mastoidectomy were included. We compared treatment for ST, specifically whether anticoagulants were given and/or if surgery was amended with an intervention aimed at the sinus. Primary outcomes include length of hospital admission, length of antibiotic treatment, otologic or neurologic complications and recanalization of the sinus.

### **Results/Conclusion**

At EAONO we would like to present our findings.

### **Discussion**

We would like to discuss the different treatment modalities for sinus thrombosis. At the moment cases like this evoke much discussion in the clinical setting with regard to optimal treatment of the ST. The goal is to reach a more harmonized approach in treatment of ST patients and provide better insights based on literature and our case series.

## PP3.12 The course of hearing loss in patients with a progressive vestibular schwannoma

Drs Kimberley S Koetsier, dr. Heiko Locher, dr. Radboud W. Koot, dr. Andel G L van der Mey, prof. Peter-Paul G van Benthem, prof. Jeroen C Jansen, dr. Erik F Hensen

<sup>1</sup>Leiden University Medical Center, Leiden, the Netherlands

### Objective

This study evaluates the natural course of hearing loss prior to treatment in patients with progressive tumors and an indication for active intervention. Evaluating this patient group specifically can put hearing outcomes after vestibular schwannoma therapy into the adequate context.

### Methods

Inclusion criteria comprised unilateral vestibular schwannomas prior to active treatment, with  $\geq 2$  mm extracanalicular tumor growth and  $\geq 2$  audiograms. We performed a comprehensive assessment of hearing using multiple outcome parameters including (the annual decrease in) pure tone averages (PTA; average of 0.5, 1, 2, 3 KHz). Predictors for hearing loss were evaluated (patient age, tumor size/progression, follow-up duration, baseline hearing).

### Results

At presentation, 86% of patients suffered from sensorineural hearing loss on the affected side ( $\geq 20$  dB PTA) with a median of 39 dB (inter-quartile rate [IQR]: 27-51 dB). Median follow-up duration was 21 months (IQR: 13-34 mo), after which 58% (187/322) of patients experienced progressive hearing loss ( $\geq 10$  dB), with a median increase of 6.4 dB/year. At last follow-up, median PTA was 56 dB (IQR: 37-73). Median speech discrimination scores deteriorated from 90% (IQR: 70%-100%) to 65% (IQR: 35%-100%). Scattergrams demonstrate progressive hearing loss over time (Figure 1). Tumor progression (maximal extracanalicular diameter) was significantly correlated to progression of sensorineural hearing loss, corrected for follow-up ( $F[2,228]=10.4$ ,  $p<0.001$ ,  $R^2=8\%$ ).

### Conclusion

The majority of patients (58%) with radiologically confirmed progressive vestibular schwannomas experience progressive sensorineural hearing loss during observation. Tumor progression rate, extracanalicular tumor extension, and longer follow-up are factors associated with more sensorineural hearing loss.

## PP3.13 Vestibular Function and Complaints in Patients with Untreated Unilateral Vestibular Schwannoma

Msc Constanza Fuentealba Bassaletti<sup>1</sup>, PhD Babette van Esch<sup>1</sup>, Msc Kenny van Lieshout<sup>2</sup>, PhD Heiko Locher<sup>1</sup>, PhD Jeroen Jansen<sup>1</sup>, PhD Radboud Koot<sup>1,3</sup>, PhD Peter Paul van Benthem<sup>1</sup>, PhD Erik Hensen<sup>1</sup>

<sup>1</sup>Department of Otorhinolaryngology / Head and Neck Surgery, Leiden University Medical Center, Leiden, Netherlands, <sup>2</sup>Institute of Education and Child Studies, Leiden University, Leiden, Netherlands, <sup>3</sup>Department of Neurosurgery, Leiden University Medical Center, Leiden, Netherlands

### Objectives

The primary aim of this study is to assess the vestibular function of patients with unilateral vestibular schwannoma and correlate their outcome to vestibular complaints and quality of life. Secondly, we evaluated patient and tumor characteristics that may affect these outcomes.

### Methods

In this cross-sectional study, patients with unilateral vestibular schwannoma aged  $\geq 18$  years were included. The participants were evaluated with caloric test, vHIT, cVEMP, DHI, PANQOL and SF-36. Tumor and patient characteristics were retrieved from the patient file. Linear regression analyses were performed to identify predictors for vestibular function.

### Results

The majority (89%) of vestibular schwannoma patients showed one or more objective vestibular abnormalities. The horizontal and anterior vHIT correlated with the caloric test results, and vHIT outcomes were correlated with hearing loss (lower gain is associated with worse hearing [ $p < 0.05$ ]) and tumor size (lower gain is associated with bigger tumors [ $p = 0.005$ ]). However, there was no significant correlation between the objective vestibular test results and vestibular complaints or quality of life. Likewise, tumor characteristics did not correlate with subjective outcomes. Even so, DHI scores showed a strong inverse correlation with PANQOL scores ( $p < 0.001$ ).

### Conclusions

Vestibular complaints have a significant impact on the quality of life in vestibular schwannoma patients. Whereas v-HIT does correlate with tumor size and hearing loss, objective vestibular function tests nor tumor characteristics correlate well with vestibular complaints or quality of life in this patient group.

